Effects of the dual orexin receptor antagonist DORA‐22 on sleep in 5XFAD mice
Abstract Introduction Sleep disruption is a characteristic of Alzheimer's disease (AD) that may exacerbate disease progression. This study tested whether a dual orexin receptor antagonist (DORA) would enhance sleep and attenuate neuropathology, neuroinflammation, and cognitive deficits in an AD...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1016/j.trci.2019.01.003 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Introduction Sleep disruption is a characteristic of Alzheimer's disease (AD) that may exacerbate disease progression. This study tested whether a dual orexin receptor antagonist (DORA) would enhance sleep and attenuate neuropathology, neuroinflammation, and cognitive deficits in an AD‐relevant mouse model, 5XFAD. Methods Wild‐type (C57Bl6/SJL) and 5XFAD mice received chronic treatment with vehicle or DORA‐22. Piezoelectric recordings monitored sleep and spatial memory was assessed via spontaneous Y‐maze alternations. Aβ plaques, Aβ levels, and neuroinflammatory markers were measured by immunohistochemistry, enzyme‐linked immunosorbent assay, and real‐time polymerase chain reaction, respectively. Results In 5XFAD mice, DORA‐22 significantly increased light‐phase sleep without reducing Aβ levels, plaque density, or neuroinflammation. Effects of DORA‐22 on cognitive deficits could not be determined because the 5XFAD mice did not exhibit deficits. Discussion These findings suggest that DORAs may improve sleep in AD patients. Further investigations should optimize the dose and duration of DORA‐22 treatment and explore additional AD‐relevant animal models and cognitive tests. |
|---|---|
| ISSN: | 2352-8737 |